AstraZeneca Poised for Potential Valuation Uplift as Heart Drug Trial Results Loom

Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during the third quarter of 2026.

Wainua functions as a TTR-silencer, inhibiting the production of transthyretin (TTR), a protein that can misfold and deposit within cardiac tissue and nerves. This accumulation leads to a degenerative condition termed ATTR-cardiomyopathy (ATTR-CM).

The CARDIO-TTRansform trial represents a phase three investigation assessing Wainua’s therapeutic efficacy in ATTR-CM patients. This indication encompasses a substantially larger and more commercially attractive patient population compared to the peripheral nerve disorder for which the drug has already secured regulatory approval.

Citi estimates a comparatively high likelihood that the trial will achieve its primary endpoint. Success would elevate the bank’s peak sales forecast for Wainua in ATTR-CM to $6 billion, rising to $7 billion when combined with revenues from the existing neurological indication. This projection significantly exceeds the risk-adjusted consensus estimate of approximately $3 billion and would translate to a 2% enhancement in Citi’s discounted cash flow valuation.

Should a secondary endpoint demonstrate clinical benefit in patients already receiving stabiliser medications, Citi anticipates peak ATTR-CM sales could reach $8 billion, with total Wainua revenues approaching $9 billion. Such an outcome would confer a 4% discounted cash flow uplift to the firm’s valuation model.

Conversely, trial failure would result in a 3% discounted cash flow reduction. However, Citi emphasises that even under this adverse scenario, its valuation would remain more than 20% above the prevailing share price. This suggests that investors should view any share price weakness stemming from disappointing trial results as a potential accumulation opportunity.